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Abstract  
Background: Accurate HIV diagnosis is critical and can be life-saving. A Rapid Test (RT) is 
considered key to HIV prevention and management. Some studies have found RT to be 
comparable with ELISA whilst others have reported on lower sensitivity.  
Aim and study design: The aim of this retrospective comparative descriptive study was to 
evaluate the sensitivity and specificity of the Tri-line HIV rapid test device in comparison to 
ELISA on patient records from Wits Oral Health Centre (WOHC) between 2014 and 2016 
Method: The study population comprised records of patients older than18 months who had 
Tri-Line HIV RT and blood drawn for ELISA on the same day. Descriptive analysis of the 
data was carried out. 
Results: The sensitivity of Tri-line was 80% (CI: 59-93%) and specificity was 100% (CI: 83-
100%). The PPV was 100% (CI: 83-100%) and NPV was 80% (CI: 65-90%). ROC area of 
0.9 at 95% CI was determined. 
Conclusion: Due to a low sample size in this study a definitive conclusion could not be 
drawn. However on the basis of the results obtained, although the tri-line RT showed lower 
sensitivity it was shown to be a clinically useful test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Acknowledgements 
My supervisors, Professor Sindisiwe Shangase and Dr Sizakele Ngwenya for their advice, 
guidance and support in the development and completion of this research report. 
Dr RE Rikhotso, Head of Department: Maxillo-Facial and Oral Surgery for granting me 
permission to access the database in the Maxillo-Facial ward where bloods were taken for 
HIV testing.  
I am grateful to my sister Mercy for assistance and support with data capturing into the excel 
spread sheet. 
Petra Gaylard, the statistician who worked with me through sample size calculation and data 
analysis for her dedication and commitment.  
Many thanks to Mr Chrismal Dela Chrismal for his endless support and continued assistance 
with additional analysis of data. 
I would like to thank my husband for his unwavering emotional and moral support throughout 
my studies including writing this research report.  
My sister Vhuli I am so thankful for all the days you took my children so I can work and 
study.   
 
 
 
 
 
 
 
 
 
 
 
v 
 
Dedication  
I dedicate this work to my husband Tami, my children (Murangi and Vhutali), my parents, my 
siblings and rest of my family and friends who supported, prayed with me and offered help 
when needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
Table of Contents 
Declaration.................................................................................................................................. ii 
Abstract ...................................................................................................................................... iii 
Acknowledgements ................................................................................................................... iv 
Dedication ................................................................................................................................... v 
Abbreviations and acronyms ................................................................................................... viii 
List of Figures ............................................................................................................................. x 
List of tables .............................................................................................................................. xi 
1. CHAPTER 1 ........................................................................................................................... 1 
1.1 Introduction and Literature review ................................................................................... 1 
1.1.1 Challenges with HIV RT ............................................................................................ 6 
1.1.2 Studies on RTs ........................................................................................................... 9 
1.1.3 The use of ELISA ..................................................................................................... 11 
1.2 Summary ......................................................................................................................... 12 
1.3 The rationale for the study .............................................................................................. 13 
1.3 Research Questions ......................................................................................................... 15 
1.4 Aim of the study ............................................................................................................. 15 
1.5. Objectives .......................................................................................................................... 16 
CHAPTER 2: Methodology ..................................................................................................... 17 
2.1 Study design .................................................................................................................... 17 
2.2 Data collection ................................................................................................................ 17 
2.2.1 Sample size calculation ............................................................................................ 17 
2.2.1 Inclusion criteria ....................................................................................................... 17 
2.2.2 Exclusion criteria...................................................................................................... 18 
2.3 Statistical methods .......................................................................................................... 18 
2.4 Ethical Approval ............................................................................................................. 19 
2.5 Protocol approval ............................................................................................................ 19 
CHAPTER 3: Results ............................................................................................................... 20 
3.1 Study population demographics ...................................................................................... 20 
3.2 Findings from ELISA and RT ........................................................................................ 23 
3.3 Discriminatory power of the Tri-line rapid test with reference to ELISA ...................... 26 
Summary of results............................................................................................................ 27 
CHAPTER 4: Discussion ......................................................................................................... 28 
4.1 Discussion ........................................................................................................................... 28 
vii 
 
Study limitations ....................................................................................................................... 33 
Chapter 5. Conclusion and recommendations .......................................................................... 34 
6. References ............................................................................................................................ 37 
APPENDIX A: ......................................................................................................................... 42 
Ethics Clearance Certificate .................................................................................................. 42 
APPENDIX B ........................................................................................................................... 43 
Protocol Approval ................................................................................................................. 43 
APPENDIX C ........................................................................................................................... 44 
Approval from the School of Oral Health Science ............................................................... 44 
APPENDIX D .......................................................................................................................... 45 
Data Collection Sheet ........................................................................................................... 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
Abbreviations and acronyms 
AB/Ab: Antibody  
AG/Ag: Antigen 
AIDS:  Acquired immune deficiency syndrome 
ART:  Antiretroviral therapy 
ARV:  Antiretroviral 
CI:  Confidence interval 
CICT:  Client-initiated counselling and testing 
CMJAH: Charlotte Maxeke Johannesburg Academic Hospital 
DNA:  Deoxyribonucleic acid 
EBV:  Epstein-Barr Virus 
ELISA: Enzyme-linked immunosorbent assay 
HAART: Highly active antiretroviral therapy     
HCT:  HIV counselling and testing  
HIV:   Human immunodeficiency virus 
HPV:  Human papilloma virus 
HSV:  Herpes simplex virus 
HTS:  HIV testing services 
IgG:  Immunoglobulin G 
IgM:  Immunoglobulin M 
KSHV: Kaposi's sarcoma-associated herpesvirus 
MSM:  Men who have Sex with Men 
NGO:  Non-governmental organisations 
NPV:  Negative Predictive Value 
ix 
 
PCR:  Polymerase chain reaction 
PICT:  Provider-initiated counselling and testing 
POCT:  Point-of-care HIV testing 
PPV:  Positive Predictive Value 
QA:  Quality assurance 
RNA:  Ribonucleic acid 
ROC:  Receiver Operating Characteristic 
RT:  Rapid HIV test 
RTs:  Rapid HIV tests 
UNAIDS: Joint United Nations Programme on HIV/AIDS 
VCT:  Voluntary counselling and testing 
VZV:  Varicella zoster virus 
WHO:  World Health Organization 
WOHC:  Wits Oral Health Centre 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Figures 
 
Figure 1.1  HIV strains, and their sub-classification into different groups and subtypes 
Figure 1.2  Sequence of appearance of laboratory markers for HIV-1 infection and 
window period for the different generations of RT 
Figure 1.3  HIV testing continuum and the patient, provider, facility and system-level 
settings where diagnostic errors and HIV misdiagnosis can occur 
Figure 3.1  Number of cases per year 
Figure 3.2  The age distribution 
Figure 3.3 Receiver Operating Characteristic (ROC) Curve for Rapid Test compared to     
ELISA (Gold Standard) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
List of tables 
Table 1.1  Different types of HIV test 
Table 1.2  Classification of oral lesions associated with HIV  
Table 2.1  Calculating estimates of sensitivity, specificity, PPV, NPV, positive and 
negative likelihood ratios 
Table 3.1  Gender of participants 
Table 3.2  Age distribution 
Table 3.3  Age and gender distribution of participants 
Table 3.4  Year of HIV Screening 
Table 3.5  HIV Test Results from ELISA and Rapid Test 
Table 3.6  Age and screening test result distribution  
Table 3.7  HIV/AIDS Related Lesions  
Table 3.8  Cross-tabulation of the Tri-line RT and ELISA results 
Table 3.9  The diagnostic indicators together with their 95% confidence intervals. 
Table 3.10  Details of ROC Curve in Figure 3.1 
 
 
 
 
 
 
 
 
 
 
 
1 
 
1. CHAPTER 1  
1.1 Introduction and Literature review 
The human immunodeficiency virus (HIV) infection is a global problem, a burden to health 
care system costing governments substantial amounts of money annually. There are two 
known primary HIV strains: HIV-1 and HIV-2; with HIV-1 found throughout the world 
whilst HIV-2 predominates in West Africa (Agbelusi et al., 2013). However given the high 
rate of intercontinental and cross-country migration the two strains can be expected anywhere 
in the world. The HIV-1 and HIV-2 strains have several subtypes. The HIV-1 strain is 
reported to have four groups: the "major" group M, the "outlier" group O, groups N and P. In 
group M there are at least nine genetically distinct subtypes (or clades) of HIV-1. These are 
subtypes A, B, C, D, F, G, H, J and K (Lihana et al., 2009, Agbelusi et al., 2013). See Figure 
1.1 below. 
 
Figure 1.1 HIV strains, and their sub-classification into different groups and subtypes 
(Agbelusi et al., 2013) 
The knowledge of the different strains of HIV is critical for all stakeholders involved in the 
diagnosis and management of HIV including associated diseases. The knowledge of the 
strains has improved diagnostic tests where currently most HIV tests incorporate both HIV 1 
& 2 and others depending on regions, the different subtypes. In a highly globalized society it 
is imperative that the country of origin of the patient being tested is considered, because the 
patient may present with an HIV strain not prevalent or seen in that particular  country.  
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It was estimated that 37 million people were living with HIV globally in 2016 (UNAIDS, 
2016). South Africa, in particular has a generalized and maturing HIV epidemic, with the 
highest number of people infected with HIV world-wide estimated at 6.4 million (National 
HIV Testing Policy and Guidelines, 2016). There are also a substantial number of individuals 
who are unaware of their HIV positive status. Hence, in South Africa HIV infection 
represents the primary burden of disease amongst young and old people. The high prevalence 
in South Africa is mainly as a result of high rates of new infections on a daily basis; and the 
scale-up of antiretroviral treatment (ART)/ highly active antiretroviral therapy (HAART)  
which has increased life expectancy among individuals living with HIV (Shisana et al., 2014, 
Bor et al., 2013).  
Intervention programs have been introduced, with education and screening at the forefront of 
these interventions to mitigate this catastrophe. The education and screening is aimed at 
educating the public about HIV and identifying individuals who have been infected so as to 
prevent re-infection or development of new infections. The key intention is to prevent the 
transmission and spread of the virus by those found to be infected once they know their 
status. The persistence of the HIV pandemic is reported to be in part the result of the inability 
to comprehensively test all at-risk individuals and failure to identify early infections (Louie et 
al., 2008).  
A comprehensive approach central to HIV intervention has been introduced in the form of 
HIV testing services (HTS) at healthcare facilities. This is aimed at reducing the impact of the 
HIV epidemic from the government and societal point of view. It is comprised of a full range 
of services provided which include: the actual HIV counselling and testing (HCT ); linkage of 
patients to appropriate HIV prevention, treatment, other clinical and support services; and 
coordination with laboratory services to support quality assurance and the delivery of correct 
results (National HIV Testing Policy and Guidelines, 2016) . Such interventions require close 
collaboration at all health service delivery system levels in NGOs, the public, and private 
sectors for the efficiency of point-of-care HIV testing (POCT). HCT is applied in the form of 
client initiated counselling and testing (CICT) previously VCT (voluntary counselling and 
testing) which is initiated by the patient, and provider initiated counselling and testing 
(PICT), which is initiated and recommended by the healthcare provider. The aim of PICT is 
early identification of patients for whom there is a high suspicion index of HIV infection due 
to presenting clinical signs and symptoms, high-risk sexual behaviour, or high HIV 
prevalence (National HIV Testing Policy and Guidelines, 2015, 2016).  
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Several methods used to test for HIV using different techniques have evolved over time in an 
effort to address the HIV/AIDS epidemic; these are shown in Table 1.1. The evolution of 
rapid tests (RTs) is focused on technologies with capabilities to detect early HIV infection 
based on the ability to detect various HIV markers as shown in Table 1.1 and Figure 1.2. In 
South Africa the recommended HIV testing involves the use of HIV RTs for children older 
than 18 months and adults utilising a specified algorithm (to be discussed below); whilst HIV 
polymerase chain reaction (PCR) is recommended for children younger than 18 months 
(National HIV Testing Policy and Guidelines, 2016). 
 
Table 1.1 Different types of HIV tests 
Type of test  HIV markers detectable 
 RNA/ 
DNA * 
Antigens Antibodies 
PCR/viral load   X   
p24 only test (Ag)   X  
4th generation antigen (P24)/antibody (Ag/Ab) tests combo: ELISA 
or newer RT combos 
 X X  
3
rd
 generation RT finger prick and oral swab test (Ab)   X 
* Viral genetic material (qualitative and quantity) 
Guide to HIV testing: http://www.i-base.info/ 
Rapid testing has been integrated into the prevention and treatment programs, providing 
access for HIV testing to numerous people. Rapid HIV testing employed as a screening and 
diagnostic test is considered one of the key interventions in the national response to HIV and 
AIDS in South Africa (National HIV Testing Policy and Guidelines, 2015). RT programmes 
have significantly increased the number of people tested for HIV globally with approximately 
60% of people reported to be aware of their HIV status in 2015 (UNAIDS, 2016).   
Figure 1.2 shows the different RTs that can be used and compares the different generation’s 
window period and the sequence of appearance of laboratory markers for HIV detection. The 
1st and 2nd generation RTs are no longer in use. The 3rd generation RT detects 
Immunoglobulin G (IgG) or Immunoglobulin M (IgM) HIV antibodies whilst the 4th 
generation RT detects p24 antigen and IgM/IgG HIV antibodies. The 4th generation is shown 
to have a shorter window period when compared to the commonly used 3rd generation RT. 
This has been attributed to the additional detection of p24 antigen. 
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Figure 1.2 Sequence of appearance of laboratory markers for HIV-1 infection and window 
period for the different generations of RT (Patel et al., 2012, Branson et al., 2014).  
The line graph shows the different laboratory markers for the different generation RT the intervals at which HIV 
infection can be detected. Eclipse period: the time after HIV acquisition when HIV RNA may be present in very 
small quantities but is undetectable.  Nucleic acid amplification testing (NAAT) appears first at about 10 days 
Acute HIV infection (AHI): phase of early HIV infection when HIV RNA and p24 antigen (at about 15 days 
after infection) are detectable but HIV antibodies (detectable at about 22 days after infection) are not. 
Immunoassay (IA); Antibody (Ab); Antigen (Ag).  
 
The 3
rd
 generation RTs are widely used standard RTs and use immunochromatography for 
the detection of HIV antibodies in whole blood collected from a finger prick, and have been 
in use since the late 1980s at numerous testing sites globally in outreach, POCT), and 
nonclinical settings (Branson, 2000, Wolpaw et al., 2010, Patel et al., 2012, Adetunji et al., 
2018). This test is a diagnostic tool of choice in resource limited areas due to low cost, 
relative ease of use, speed in obtaining results (≤ 30 minutes). Furthermore it minimizes the 
rate at which clients fail to return for test results (Wolpaw et al., 2010, Patel et al., 2012, 
Moodley et al., 2008). It is a convenient and non-invasive practical way to provide 
information about HIV status on an individual basis and in large groups of people with results 
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available on site during the same visit (Kassler et al., 1997, 1998). The test is performed in 
the presence of the patient thus incorrect labelling of the specimen is minimized (Moodley et 
al., 2008). Other HIV RTs make use of saliva samples that are also interpreted at the point of 
testing (Pilcher et al., 2010).  
To promote access to POCT, HTS has been extended to non-health care facilities and 
integrated into community HIV prevention programmes (Bock et al., 2017). This promotes 
access to HIV screening and informs health authorities on possible intervention strategies in 
centres where individuals or groups can be accessed and where access to laboratory services 
is limited (Johnson et al., 2015); such as in outreach programmes where RTs are crucial for 
timely identification of individuals infected with HIV, and for instituting HIV prevention 
strategies including treatment (Louie et al., 2008). High levels of competencies have been 
shown amongst counsellors in outreach programmes at community level in studies done in 
South Africa and Malawi (Jackson et al., 2013, Molesworth et al., 2010, Bock et al., 2017).  
HIV RTs allow a timeous identification of those infected with the virus in emergency rooms, 
doctor's consultation rooms, and clinics to facilitate appropriate treatment (Louie et al., 
2008). This is especially in cases where establishing a diagnosis of HIV infection is critical 
for clinical decision-making and timely provision of appropriate therapy (National HIV 
Testing Policy and Guidelines, 2015) as an HIV diagnosis can be life-saving. This forms part 
of the PICT to aid in the management of patients and also support the upscaling of HIV 
testing as part of HIV prevention strategy.  
The HIV testing algorithms were introduced to improve the accuracy of HIV testing; and 
involve the use of RTs that have been designed to achieve predictive values close to 100 %, 
either in sequence (serial testing) or parallel (parallel testing). In parallel testing two RTs are 
used simultaneously each test being a check on the other (Mbachu et al., 2015) and when 
there is discordant results, a third RT is used as a tiebreaker. This approach has been 
challenged and reported to result in high rates of misdiagnosis (Johnson et al., 2017a, b). 
Serial testing on the other hand involves the use of two RT kits with sensitivity ≥ 99% as per 
WHO (World Health Organization) recommendations (Mbachu et al., 2015) and is the 
recommended approach in South Africa. A serial 2-test algorithm for HIV diagnosis has been 
recommended for RTs that allows linkage of the individual to appropriate services. The 2 
tests constitute an initial screening RT and a second confirmatory RT (National HIV Testing 
Policy and Guidelines, 2015).  
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In the recommended serial 2-test algorithm, the 2 antibody RTs are employed sequentially 
with serial laboratory based ELISA (enzyme-linked immunosorbent assay) tests where 
needed as follows (National HIV Testing Policy and Guidelines, 2016): 
1. When the screening RT is reactive, a confirmatory RT is then performed to confirm 
the positive result of the screening test. If the confirmatory test is reactive then the 
diagnosis is positive for HIV.  
2. When the screening test is non-reactive then the diagnosis is negative for HIV and 
result should be reported as such. However the possibility of recent exposure must be 
considered and when deemed necessary the period of re-testing should be determined.  
Retesting for window period is recommended after six weeks from the possible date 
of exposure and should be determined based on patient’s perceived risk to help 
determine the frequency.  
3. When there is discrepancy between the 2 tests then the tests are to be repeated 
immediately, if still discordant then whole blood is drawn for an ELISA test which is 
employed as a tiebreaker in determining the HIV status. The patient is then requested 
to return within seven days for the results which can take up to 2 weeks.  
4. In the laboratory a serial testing algorithm using fourth generation ELISA is 
conducted. If the initial ELISA result is non-reactive, a negative result is reported, and 
if results are reactive, a positive result is reported. When the results of the two ELISA 
tests are discordant and not resolved by further re-testing the HIV testing should be 
repeated after six weeks or as determined based on assessed patient risk.  
 
There are currently several HIV rapid diagnostic tests and all the WHO prequalified RTs 
have a sensitivity of ≥99% and specificity ≥98% and are reported to be accurate when used 
correctly in a validated national testing algorithm (WHO, 2004, Johnson et al., 2017a).  
 
1.1.1 Challenges with HIV RT 
The standard RTs only test antibodies against HIV, and individuals only test positive after 
seroconversion, which is the time between infection and the generation of detectable 
antibodies. Hence it is reported that although the sensitivities of rapid HIV tests for 
established HIV infection are high, the results are variable when it comes to the detection of 
HIV infection prior or during the early seroconversion period (Patel et al., 2012). A RT that 
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tests for antibodies in whole blood would read negative if the patient has not seroconverted or 
in those with agammaglobulinaemia or severe immunosuppression, who even though 
infected, may not have sufficient and detectable antibody titres. Patients often find it 
particularly difficult to understand that a negative result can be positive 3 to 6 weeks later. A 
study by Patel and colleagues highlights missed opportunities for HIV diagnosis and 
prevention. In their study the researchers found that RTs failed to detect early HIV infection 
in half of the cases studied. Sensitivities for early HIV infection ranged from 55–57% with 
the third generation and 76–88% with the fourth generation RTs (Patel et al., 2012). This is in 
agreement with Figure 1.2 that shows the time lines following exposure to HIV to 
identification of HIV infection or missed diagnosis depending on RT used.  
Individuals with false negative results can transmit the infection to others, thus making the 
intervention programmes counterproductive. The communication of inconclusive HIV results 
and coping with the uncertainties that come with it, is difficult for both the health care 
provider and the patient (Johnson et al., 2017a).  Those who test whilst on HAART may also 
test negative and if not followed up they may think they are cured and default on treatment; 
hence the importance of education and need for laboratory HIV testing. These and other 
factors are the primary drivers for a decreased sensitivity with RT (Bock et al., 2017).  
Rapid tests in infants pose challenges as infants may receive antibodies from an infected 
mother and test positive as a result, even when not infected. Moreover, infants, due to their 
underdeveloped immune systems, may not produce antibodies in response to the HIV 
infection and subsequently have negative test results (WHO, 2005). Hence in this group of 
patients the PCR test is most suitable, especially for those under 18 months old (National 
HIV Testing Policy and Guidelines, 2016).  
Studies have shown that on site RTs do not yield the same accuracy as tests performed in 
laboratories (Moodley et al., 2008, Wolpaw et al., 2010, Bock et al., 2017). Although RTs 
increase HIV status awareness in large communities, they often fail to detect early HIV 
infection with resultant dire consequences and missed opportunities for HIV prevention 
(Patel et al., 2012). It has also been suggested that RT kits may underperform and fail to 
detect a substantial number of infected individuals (Wolpaw et al., 2010, Patel et al., 2012). 
This also works against the national strategic plan to reduce HIV infections by 50% (National 
HIV Testing Policy and Guidelines, 2015) and the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) goal to identify 90% of individuals infected with HIV by 2020. The 
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ability to detect HIV infection in recently infected individuals is of paramount importance 
because the highest rate of HIV transmission per coital act has been found to occur in the 
early stage of infection (Wawer et al., 2005). The early infections contribute significantly to 
high prevalence of HIV infection (Shisana et al., 2014, Patel et al., 2012).  
Although high levels of competencies have been shown for RTs, even amongst lay 
counsellors, inadequate quality assurance (QA) and user error contributes to poor 
performance of RTs leading to misdiagnosis (Bock et al., 2017). This was shown in a study 
that reported higher sensitivity and specificity when RTs were performed by skilled 
laboratory technicians in comparison to lay counsellors and nurses (Moodley et al., 2008). 
Human error and suboptimal testing strategies are reported to have a significant impact on 
HIV misdiagnosis (Johnson et al., 2015, Johnson et al., 2017b, Bock et al., 2017). Figure 1.3 
depicts several points in the HIV testing continuum where misdiagnosis and errors can occur. 
As depicted on Figure 1.3, HIV misdiagnoses and testing errors cannot be pinned down to a 
single cause or underlying factor as the diagnostic errors can occur across multiple steps 
within the HIV testing continuum (Johnson et al., 2017a).  
One of the challenges is the subjectivity in the interpretation of positive bands on RTs 
especially the weak positive bands (Gray et al., 2007) that can be interpreted as false negative 
or positive. In their study, Wolpaw et al., 2010 found the most significant contributor to 
inaccurate results to be errors in the administration of tests and not following the 
recommended testing algorithm. Johnson et al. confirmed that the use of suboptimal testing 
algorithms was the cause for misdiagnosis especially in false positive results. In the same 
review the researchers found that retesting of patients on HAART was the most common 
cause of false negative results (Johnson et al., 2017b).   
The reported reduced sensitivity and specificity devalue the long term cost effectiveness of 
RTs. Furthermore Moodley and colleagues emphasised user dependent reliability of RTs, 
particularly in the interpretation of weak positive band on test devices (Gray et al., 2007, 
Shanks et al., 2013, Klarkowski et al., 2014). This finding is corroborated by Mwisongo and 
colleagues who observed that the quality of RT is highly compromised by poor adherence to 
manufacturer’s guidelines (Mwisongo et al., 2016). 
Although current commercialised RTs meet the required international performance 
specifications; there are manufacturer variations in sensitivity and specificity which have a 
significant impact on the sensitivity (ability of the kit to correctly detect specimens 
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containing HIV antibodies) and specificity (ability of the kit to correctly detect specimens 
that do not contain HIV antibodies) (Moodley et al., 2008, Mwisongo et al., 2016).  
 
Figure 1.3: HIV testing continuum and the patient, provider, facility and system-level 
settings where diagnostic errors and HIV misdiagnosis can occur. From Johnson et al., 2017b 
HIV misdiagnosis with RTs is believed to be under-reported.  The contributing factors 
include programme reputation and publication bias (Johnson et al., 2017a). This 
underreporting limits discussions and investigation that are required to determine possible 
causes of misdiagnosis so that efforts can be made to address them systematically. This is 
important as misdiagnosis has deleterious individual and public health implications.   
1.1.2 Studies on RTs    
A study in five African cities including Durban in South Africa assessed three HIV rapid 
antibody tests (the OraQuick, Determine, and Unigold) found the RTs to have high sensitivity 
and specificity, similar to or slightly below the values indicated in the package insert for each 
test kit. Whilst all test kits achieved above 98% sensitivity and specificity none demonstrated 
100% sensitivity and 100% specificity (Piwowar-Manning et al., 2010). In another study 
from Uganda evaluating three RTs namely, Determine HIV-1/2/O, Stat-Pak Ultra-Fast, and 
Uni-Gold Recombinant HIV-1/2 test against ELISA reported low sensitivity and specificity. 
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Of 295 positive results, 129 were found to be false positive whilst 4 of 1222 negative results 
were false negative. Of the 129 false positive results, 123 were obtained from Determine and 
Uni-Gold tests (Gray et al., 2007). In addition the researchers found 37 samples with weak 
positive bands to be negative on ELISA and Western blot. Overall 94% of weak positive 
bands were not confirmed as positive by ELISA (Gray et al., 2007).  
A study conducted in a clinic in Cape Town reported on a period during which rapid HIV 
testing sensitivity was estimated at 68.7% with more than 1,100 HIV positive individuals 
having received negative results (Wolpaw et al., 2010). In this study after the change of one 
RT to another, the sensitivity was increased to up to 95%.  Moodley and colleagues however, 
in their study found that HIV rapid test results were comparable with ELISA results 
especially when performed by laboratory technicians with sensitivity and specificity at 100%. 
They reported sensitivity and specificity of RTs up to 97% and 98% by lay counsellors and 
nurses respectively (Moodley et al., 2008). The four RTs included in the study were: First 
Response HIV Card 1-2-0; Pareekshka HIV Triline; Abbott Determine HIV 1\2; and Sensa. 
In another study in India RTs fared poorly when compared to ELISA (Mehra et al., 2014). 
In view of the limited ability of antibody-only-RTs to detect acute HIV infection, a 4th 
generation RT capable of detecting HIV antibodies and the p24 antigen has been introduced 
(Chetty et al., 2012, Beelaert and Fransen, 2010). Combination of the 2 technologies in a RT, 
facilitates the detection of early infections prior to seroconversion, particularly during the 
acute phase of infection when individuals are highly infective and asymptomatic (Chetty et 
al., 2012, Beelaert and Fransen, 2010). This early detection of acute HIV infection is 
important for clinical diagnosis and the prevention of viral transmission. This combo test 
should be considered an alternative diagnostic and screening tool for antigen detection in 
high-risk population groups in resource constrained settings.   
The 4
th
 generation RT in one study was reported to detect early HIV infection in 76% of 
studied specimens which was twice that of the 3
rd
 generation RT (Patel et al., 2012), similar 
to the findings by Beelaert and Fransen, 2010. In the latter study, the 4
th
 generation RT was 
able to detect 82% acute HIV infection in specimens due to the sole presence of the HIV Ag 
bar in the combo test and showed a higher sensitivity when compared to the antibody only 
test. Although a significant number of early infections were detected, five of the seven 
negative results were weakly reactive and the remaining two were positive when tested by 
Vironostika ELISA test and with the Vironostika ELISA test. The Determine
TM
 RT thus 
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showed lower sensitivity (82%) for acute infections than the 92% sensitivity attained with the 
Vironostika ELISA test (Beelaert and Fransen, 2010). 
A Kwazulu-Natal study on pregnant women evaluated a 4th generation antigen/antibody RT  
against a 3rd generation antibody RT and found that although the 4th generation RT was not 
able to detect acute HIV infection,  it showed superior sensitivity in antibody detection when 
compared to the widely used 3rd generation RTs (Chetty et al., 2012).   
From the studies above, the antigen and antibody RTs are shown to be less sensitive than the 
ELISA and detect HIV antigens when the viral load is high (Beelaert and Fransen, 2010, 
Eshleman et al., 2018). The variability in RT sensitivity favours the use of ELISA as a 
mainstay intervention particularly in high risk individuals. 
1.1.3 The use of ELISA 
The use of immunoassay technology, the gold standard for HIV diagnosis, has improved 
substantially over time, with most tests replaced by 4
th
 generation HIV-1 and -2 antigen plus 
antibody combination immunoassay (Miller, 2015). Although false negative and positive 
results are possible the 4
th
 generation immunoassay tests are reported to be more sensitive 
and specific as they can be reactive even prior to seroconversion. The interval between 
infection and a reactive result is reported to be 14-21 days (Miller, 2015). The increased 
sensitivity of the 4
th
 generation immunoassay was also shown by Patel and colleagues who 
found RT sensitivity for early HIV infection to range from 22-33% compared to 76–88% for 
the 4
th
 generation immunoassay (Patel et al., 2012). However Moodley and colleagues found 
that 98% -100 % of HIV rapid test results were comparable with ELISA (Moodley et al., 
2008). 
Beelaert and Fransen, 2010 found in their study that the 4th generation Determine
TM
 HIV-1/2 
Ag/Ab combo RT exhibited a slightly lower sensitivity for the detection of viral Ag when 
compared to the Vironostika HIV Uni-Form II Ag/Ab ELISA test. The lower sensitivity of 
the 4
th
 generation RT in comparison to the 4
th
 generation ELISA was also reported by Patel 
and colleagues (Patel et al., 2012). Thus the antigen and antibody HIV RTs were reported to 
be less sensitive than the ELISA and detect HIV antigen when the viral load is high (Beelaert 
and Fransen, 2010, Patel et al., 2012, Eshleman et al., 2018). From the above studies ELISA 
has shown higher sensitivity than 3rd and 4
th
 generation RTs, hence it is considered the gold 
standard when it comes to HIV testing. 
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Although ELISA is the gold standard, its widespread use is hampered by several factors 
including complexity in the collection and processing of venous blood, the transportation and 
appropriate storage of the specimens, particularly in resource-poor settings, where access to 
electricity or refrigeration may be inadequate or absent (Pilcher et al., 2010). In addition, 
laboratory testing may also have errors with sample mislabelling leading to patients receiving 
false results. Hence RTs, have been widely adopted as the standard of care in most testing 
sites and identification of those infected remains the cornerstone of a global HIV infection 
prevention strategy (Pilcher et al., 2010). 
1.2 Summary  
HIV RTs are important health promotion tools and their usage increases awareness of HIV 
status. They have also paved the way for use in non-health facilities and emergency units 
other than recognized clinics in areas with increased HIV infections (Pilcher et al., 2010).  
Due to the challenges faced when testing infants it is recommended that, results be 
interpreted with caution given an increased rate of false negative and false positive results in 
this population (WHO, 2005). The specificity and sensitivity of RTs are unreliable in infants 
and are largely dependent on timing of the test in relation to the period during which the 
infection was acquired.  
The prevention of new infections and/ or re-infections in a country like South Africa where 
multiple new infections occur daily necessitates more accurate and reliable tests to be 
administered as part of the HTS prevention and treatment programme. Although, some 
studies have reported the performance of RTs and laboratory-based enzyme-linked 
immunosorbent assay (ELISA) to be comparable (Moodley et al., 2008, Mehra et al., 2014), 
concerns regarding sensitivity and specificity of the RTs (Gray et al., 2007, Wolpaw et al., 
2010) warrant significant consideration given that the sensitivity and specificity of RTs may 
be affected by user training and competency, testing environments, the testing algorithm 
used, test kit handling and storage as well as performance of a specific test kit (Bock et al., 
2017).   
Previous studies have demonstrated the limitations of the 4th generation RT when compared 
to ELISA (Chetty et al., 2012, Beelaert and Fransen, 2010, Eshleman et al., 2018). With the 
reduced sensitivity and specificity, the long term cost effectiveness of the 4
th
 generation RTs 
has to be thoroughly interrogated.  
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Although the use of ELISA bears great advantage over RTs, the need for adequate laboratory 
infrastructure makes it inappropriate for use at on-site testing facilities considering the current 
infrastructure and resource constrains.  
1.3 The rationale for the study 
This study was based on an observation made in the Oral Medicine clinic at the WOHC 
where a number of patients who presented with Group 1 lesions as described in the EC-
Clearinghouse Classification (Table 1.2) and were testing negative with RTs and positive 
with ELISA when requested. Following this a request was made for patients presenting with 
such lesions to have both tests performed. Although meant for European and United States 
populations, this classification is widely used in other parts of the world including Africa. 
Consensus on the classification of the oral manifestations of HIV infection and their 
diagnostic criteria based on presumptive and definitive criteria was reached in 1992. The 
presumptive criteria alludes to the clinical appearance of the lesion (high suspicion index for 
suspected lesion/condition) whilst the definitive criteria refers to diagnosis following special 
investigation (ECC/WHO, 1993).  
The EC-Clearinghouse Classification groups lesions into Group 1, 2 and 3; based on the 
frequency of their occurrence amongst HIV positive patients (see Table 1.2). Group 1 lesions 
represent those lesions commonly seen with HIV infection. Hence, in clinical practice, where 
a person’s HIV status is unknown and presents with such lesions, there should be a high 
suspicion index for HIV infection (Maeve et al., 2005, Shangase et al., 2004) and such 
patients should be tested. The first line test in the clinic is the RT. For patients presenting 
with Group 1 lesions the two testing techniques are recommended even if the RT results are 
negative. Some of the lesions in group 2 and 3 such as HPV infections, TB, salivary gland 
enlargement, herpes zoster, etc. are common in our setting and when present are highly 
suggestive of HIV.  
Oral lesions may be the first clinical signs suggestive of HIV infection and may thus be used 
for early clinical diagnosis and management of such patients(Greenspan et al., 1992, 
Agbelusi et al., 2013). Expectedly, the oral cavity is a reservoir for most micro-organisms 
that cause oral lesions associated with HIV. These include viruses (KSHV, EBV, and HPV 
etc.), Candida albicans, and several bacterial species; and co-infection with HIV may lead to 
their reactivation or potentiation of their virulence.  
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Increased awareness of lesions strongly associated with HIV in the public and amongst other 
health care providers outside dentistry is necessary. This can assists key stakeholders in 
education, prevention programmes and integration of oral health when developing 
interventions to curb the epidemic. 
Table 1.2. Classification of oral lesions associated with HIV 
Group 1: Lesions strongly associated with HIV 
infection  
Candidiasis: 
  Pseudomembraneous candidiasis 
  Erythematous candidiasis 
  Angular cheilitis 
Hairy leukoplakia 
Kaposi’s sarcoma 
Non-Hodgkin’s lymphoma 
Periodontal diseases 
  Linear gingival erythema (LGE) 
  Necrotizing periodontal diseases 
Group 2: Lesions less commonly associated with 
HIV Infection 
Bacterial infections:  
  Mycobacterium tuberculosis 
Melanotic hyperpigmentation 
Necrotizing (ulcerative) stomatitis 
Salivary gland disease 
  Dry mouth due to decreased salivary flow 
  Unilateral/bilateral swelling of salivary glands 
Thrombocytopenia purpura 
Non-specific ulcerations  
Viral infections: 
  Herpes simplex virus (HSV) 
  Varicella-zoster virus (VZV) 
  Herpes Zoster 
  Human papillomavirus (HPV) 
       Condyloma acuminatum 
       Focal epithelial hyperplasia 
       Verruca vulgaris 
Group 3: Lesions seen in HIV infection 
Bacterial infections: 
  Actinomyces israelii 
  Escherichia coli 
  Klebsiella pneumonia 
  Cat-scratch disease 
  Epitheliod (bacillary) angiomatosis 
Drug reactions (ulcerative, erythema      multiforme, 
lichenoid, toxic epidermolysis) 
Fungal infection other than candidiasis 
Cryptococcus neoformans 
  Geotrichum candidum 
  Histoplasma capsulatum 
  Mucoraceae (mucomycosis/zygomycosis) 
  Aspergilus flavus 
Neurological disturbances: 
             Facial palsy 
             Trigeminal neuralgia 
 
Adapted from ECC/WHO, 1993. EC-Clearinghouse and WHO Collaborating Centre on Oral 
Manifestations of HIV infection 
The routine testing protocol applied at the WOHC (Wits Oral Health Centre) is as 
follows: Patients are informed and counselled before and after testing regardless of the 
results. The RT is performed after obtaining the patient’s informed consent. For positive or 
discordant results venous blood is drawn for ELISA.  The ELISA used during the period of 
the study was the 4th generation Siemens Advia Centour assay that detects HIV p24 Antigen 
and Antibodies to HIV 1, Including Group O (HIV-1 + “O”) and/or HIV-2. If the RT result is 
negative, it is accepted as such and no further testing is done. The RT test used at WOHC as 
first line is the ABON™ HIV 1/2/O Tri-Line HIV RT device (ABON Biopharm (Hangzhou) 
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Co. Ltd, China) referred to in the text as Tri-line. The HIV 1/2/O Tri-line HIV rapid test 
device used is a rapid chromatographic immunoassay for the qualitative detection of 
antibodies to HIV-1, including subtype O, and HIV-2 in venous and capillary whole blood, 
serum and plasma specimens. The product can be used as an aid in the diagnosis of HIV 
infection.  It was accepted for the WHO list of prequalified HIV diagnostics and was listed on 
25 August 2014 (WHO PQDx Public Report, 2017). The use at the WOHC appears to have 
been before this acceptance into the WHO list of prequalified HIV diagnostics. This RT is 
reported to have 99.9% relative sensitivity and 99.8% relative specificity as per manufacturer 
information leaflet. 
HIV tests were administered by nurses trained on HTS in the Maxillo-Facial and Oral surgery 
ward. The patients tested were referred mainly from the Oral Medicine and Maxillo-Facial 
and Oral surgery clinics. 
The Tri-line RT is used for screening. The confirmatory tests used were the First Response 
HIV 1-2-0 Card Test was used in 2014-2015 and Advanced quality Rapid HIV Test in 2016. 
The parallel testing approach is also used, this however is not practiced routinely it would 
seem the algorithm used depends on the nurse performing HTS at a particular time. With the 
parallel testing algorithm the two rapid tests mentioned above are used simultaneously, and if 
discordant the tests are repeated 2 to 3 times and if still discordant then blood is drawn for 
ELISA.  
In the data extracted from the patients records between 2014 and 2016 both RTs were 
concordant in all patients.  
 
1.3 Research Questions 
What is the sensitivity, specificity and discriminatory power of the Tri-line RT in comparison 
with ELISA? 
1.4 Aim of the study 
The aim of this study was to evaluate the sensitivity and specificity of the HIV 1/2/O Tri-line 
HIV rapid test device in comparison with ELISA as the gold standard in patient records from 
the WOHC at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH).   
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1.5. Objectives 
The objectives of the study were: 
 To collate records of all patients at the WOHC who had been tested for HIV at the 
same visit using the HIV 1/2/O Tri-line HIV rapid test device and ELISA.  
 To report on negative and positive results for both the RT and ELISA performed at 
the same visit.  
 To report on the sensitivity, specificity, PPV (positive predictive value), NPV 
(negative predictive value), positive and negative likelihood ratios of the HIV RT for 
detection and exclusion of HIV infection in comparison to the gold standard 
laboratory test ELISA.  
 To determine the clinical usefulness of HIV 1/2/O Tri-line HIV rapid test device. 
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CHAPTER 2: Methodology 
2.1 Study design 
This is a retrospective comparative descriptive pilot study conducted on the records of 
patients seen and tested for HIV between 2014 and 2016 at the WOHC. Patients included in 
the study were tested for HIV with the ABON™ HIV 1/2/O Tri-Line HIV RT device [ABON 
Biopharm (Hangzhou) Co. Ltd, China] and the 4th generation ELISA: Siemens Advia 
Centour assay that detects HIV p24 Antigen and Antibodies to HIV 1, including Group O 
(HIV-1 + “O”) and/or HIV-2.  
2.2 Data collection 
Data was collected from 111 medical records of patients who were tested for HIV at WOHC 
from 2014 to 2016. Approval to access the WOHC HIV test register was obtained from the 
relevant authority, the letter is attached as Appendix C.  
The medical records were retrieved from the WOHC database and the following data were 
extracted and recorded in a structured data collection sheet: year of testing; age; gender; 
ELISA test results (positive / negative), if positive, CD4-T cell count where available; and 
Tri-line HIV rapid test result (positive / negative). The data collection sheet is attached as 
Appendix D.  The patient data evaluation was retrospective and anonymous; and informed 
consent was not required. Each eligible patient record was assigned a study number and data 
extracted from the patient’s HIV register were entered into a pre-designed excel spread sheet. 
2.2.1 Sample size calculation 
For the estimation of sensitivity and specificity at levels of 98% and 95%, respectively, with 
2% precision, at the 95% confidence level, with a prevalence of HIV of 80% in the study 
group, the sample size calculated for the study was N = 2281. Sample size requirements were 
based on the key research question, namely the determination of the sensitivity and 
specificity of the Rapid Test. The sample size calculations were carried out in G*Power 
(Buchner, 2007). 
2.2.1 Inclusion criteria 
Medical records of patients 18 months and older, who had been counselled and from whom 
informed consent to have the HIV test done, had been obtained.  Medical records from 2014-
to 2016 indicating a Tri-line test administered on the same day venous blood was drawn for 
ELISA were included in the study.  
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2.2.2 Exclusion criteria 
 Medical records where consent was not obtained. 
 Medical records where only one of the tests was performed.  
 Medical records where tests were conducted using the HIV 1/2/O Tri-line HIV rapid 
test and ELISA at different visits. 
 Medical records of patients younger than 18 months. 
2.3 Statistical methods 
Descriptive analysis of the data was carried out as follows:  Categorical variables were 
summarised by frequency and percentage tabulation, and illustrated by bar charts.  
Continuous variables were summarised by the mean, standard deviation, (or median and 
interquartile range), and their distribution illustrated by histograms. 
 
Estimates of sensitivity, specificity, PPV (positive predictive value), NPV (negative 
predictive value), positive and negative likelihood ratios were determined, together with their 
95% confidence intervals. These quantities were calculated as shown in Table 2.1  
 
Table 2.1. Calculating estimates of sensitivity, specificity, PPV, NPV, positive and negative 
likelihood ratios 
 True status (ELISA) 
Condition Positive Condition Negative 
Test outcome  
(Rapid test) 
Test Positive True positive (TP) False positive (FP) 
Test Negative False negative (FN) True negative (TN) 
Sensitivity = TP / Condition Positive   Specificity = TN / Condition Negative 
Positive Predictive Value = TP / Test Positive  Negative Predictive Value =TN / Test Negative 
Positive Likelihood Ratio = Sensitivity / (1-Specificity) Negative Likelihood Ratio = (1-Sensitivity) / 
Specificity 
 
Data analysis was performed using a statistic program (STATA). Quantitative data was 
summarized in tables and figures and described using medians and ranges; counts with 
percentages (%); the Fischer’s exact test; and the Mann-Whitney U test. A p-value of <0.05 
was considered statistically significant. 
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A Receiver Operating Characteristic (ROC) curve was drawn to determine the discriminatory 
power of the Tri-line Rapid Test kit compared to ELISA (gold standard). The area under a 
ROC curve specifies the discriminatory power of the diagnostic test. A theoretically perfect 
diagnostic test records an area of 1.0 which signifies a sensitivity of 100% and specificity of 
100% (Fan et al., 2006, Hajian-Tilaki, 2013).  A ROC area of 0.0 signifies a specificity of 0% 
and sensitivity of 0%, indicating a theoretically imperfect test. Statistically, a diagnostic test 
of ROC area equal to or less than 0.75 is not clinically useful while a ROC area of greater 
than 0.75 is clinically useful. A test with a ROC area of more 0.97 and above is deemed very 
useful (Fan et al., 2006). 
“Discriminatory power” is the extent a test score recorded by an instrument varies with 
regards to differences in traits with the aim of distinguishing subjects or participants with 
high traits from those with low traits (Ferrando, 2012). In this study, it is the ability of the 
Tri-line RT to distinguish between individuals with HIV positive results from those with HIV 
negative results. Discriminatory power predicts the clinical usefulness of a diagnostic tool. 
2.4 Ethical Approval 
Ethical clearance for this study was obtained from the Human Research Ethics Committee of 
the University of the Witwatersrand, Johannesburg, South Africa, under the protocol number 
M170572 (Appendix A).  
2.5 Protocol approval 
The protocol was assessed and approved by the assigned assessors and the dedicated 
committee (Appendix B). 
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CHAPTER 3: Results 
3.1 Study population demographics 
A total of 111 medical records were reviewed, out of which 45 met the inclusion criteria. The 
available sample size of 45 patients corresponds to a precision of 14%, rather than 2%. Hence 
it is understood that this is a pilot study. 
Sixty six records excluded from the study comprised records where only one of the tests was 
performed and those where the Tri-line test and ELISA were performed independently at 
different visits. In 2 medical records the ELISA and RT were conducted 3-4 days apart. One 
patient had tested positive with both tests whilst the other tested negative with both tests. It 
can be argued that these 2 records could have been added to the study group. The inclusion 
criteria were adhered to; to prevent result bias, maintain objectivity and control of the study. 
Furthermore, the statistician further advised that their inclusion would not have a significant 
impact on the results; therefore, the 2 records were excluded from the study.   
Two medical records with negative result with the Tri-line test were also excluded: one 
patient tested positive 2 months later with ELISA whilst the other patient had an 
indeterminate result. The second patient, whose results were indeterminate, was diagnosed 
with deep fungal infection. The patient who tested positive 2 months later with ELISA was 
diagnosed with Kaposi’s sarcoma.  
In six medical records where both tests were conducted, the Tri-line results were not recorded 
in 3 whilst in the remaining 3 ELISA was performed but results were not available. The 
remaining records comprised 15 needle stick injuries where ELISA was not done as per 
protocol at the WOHC, and the in remaining 41 medical records ELISA was not done. Of the 
excluded records 6 had an HIV positive RT result whilst 54 had HIV negative RT results. 
The RT results were not recorded in 6 other excluded medical records.  
The majority of the study population was female (61%) as shown in Table 3.1. The average 
age was 35 years with a range from 3 to 61 years (Table 3.2).  Most cases were recorded in 
2015, with only one case in 2014 (Table 3.4 and Figure 3.2). 
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Table 3.1: Gender of participants 
 
Variable Variable n % 
Gender F 27 61 
M 17 39 
Not specified 1   
Table 3.1 shows that the majority (61%) of the participants included in this study are female.  
Age was recorded in 42 patients, with 3 patients whose age was not recorded. Thus in terms 
of age there was 7% missing data. The mean age of the patients was 35 years with a SD =14 
years and a range of 10-70 years as shown in Table 3.2 above. 
From Table 3.3, 26 out of the 42 participants with identified age were female in gender. 
 
Table 3.2 Age distribution 
Age (years) 
N Mean SD Median Interquartile 
range 
Minimum Maximum 
42 35.1 13.9 33 26 46 10 70 
 
 
 
 
Figure 3.1 The age distribution 
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Table 3.3: Age and gender distribution of participants 
Age Category 
(3 missing) 
Gender (1not specified)  
Total Male  Female 
0-20 years 1 2 3 
21-40 years 10 17 27 
Above 40 years 5 7 12 
Total 16 26 42 
 
The majority (60%) of the participants included in this study were screened in the year 2015 
whilst 17 (38%) and 1 (2%) were screened in the year 2016 and 2014 respectively (Table 
3.4).  
 
 
Table 3.4: Year of HIV Screening 
 
Variable Variable n % 
 
 
 
Year 
2014 1 2 
2015 27 60 
2016 17 38 
 
 
 
 
Figure 3.2 Number of cases per year 
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3.2 Findings from ELISA and RT 
The results of the HIV screening test conducted using the two screening tools (ELISA and 
Tri-line) were different. Of the 45 medical records that met the inclusion criteria ELISA test 
results show 20 participants (44%) were negative whereas Tri-line found 25 participants 
(56%) negative (Table 3.5). Twenty five of these records had a positive outcome with 25/45 
(56%) testing HIV positive with ELISA and 20/45 (44%) with Tri-line RT. 
Table 3.5: HIV Test Results from ELISA and Rapid Test 
Variable Variable n % 
ELISA test NEGATIVE 20 44 
POSITIVE 25 56 
Rapid Test NEGATIVE 25 56 
POSITIVE 20 44 
 
Table 3.6 shows that the majority (28) of the participants included in the study were between 
the ages of 21 and 40. The ELISA test result found 8 participants within this category to be 
negative and 19 positive. The RT on the other hand found 10 of them negative and 17 
positive. Twelve of the participants were above 40 years. ELISA found six participants in this 
category to be negative and 6 positive whereas rapid test detected 9 of them as negative and 2 
of them as positive. Three of the participants were between the ages of 0 and 20. The ages of 
three participants were missing from the data available to the researcher. ELISA and RT 
results of the 0-20 year category and the missing category were the same, i.e. all being 
negative. 
Table 3.6: Age and HIV test result distribution  
 
Age Category 
ELISA Test Tri-line Rapid Test  
Total Positive Negative Positive Negative 
0-20 years 0 3 0 3 3 
21-40 years 19 8 17 10 27 
Above 40 years 6 6 3 9 12 
Missing 0 3 3 0 3 
Total 25 20 25 20 45 
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Seven of the 45 participants included in this study had oral lesions strongly associated with 
HIV/AIDS recorded; five had candidiasis, one Kaposi’s sarcoma and one plasmablastic 
lymphoma. ELISA test detected all the participants with lesions as HIV positive. The RT on 
the other identified four of the participants with candidiasis as HIV positive and those with 
Kaposi’s sarcoma and plasmablastic lymphoma as HIV negative (Table 3.7). 
The CD4-T cell count was also recorded, however with more than 30% of the data missing in 
the ELISA-positive cases; the data could not be analysed. Attention can however be drawn to 
the one patient with a false HIV negative Tri-line result and a CD4-T cell count of 36 cell/µL. 
A patient from Sudan had a CD4-T cell count of 264 and tested negative with both Tri-line 
and ELISA 
Table 3.7: HIV associated oral lesions  
 
Lesions  
ELISA Test Tri-line Rapid Test  
Total Positive Negative Positive Negative 
Candidiasis 5 0 4 1 5 
Kaposi’s sarcoma 1 0 0 1 1 
Plasmablastic 
lymphoma 
1 0 0 1 1 
High grade 
Malignant 
Haematolymphoid 
neoplasia 
1  1  1 
Ulcer NOS 1  1  1 
Squamous 
papilloma 
 1  1 1 
Total 9 1 6 4  10 
 
Twenty five (56%) of the 45 cases screened in this study period tested positive for HIV with 
ELISA whilst the remaining 20 (44%) tested positive with Tri-line RT. Of the 25 patients 
who tested positive with ELISA, 20 also tested positive with Tri-line with five patients 
testing false negative for HIV with the Tri-line test (Table 3.8). No patients were found to be 
positive with the Tri-line test and negative with ELISA and thus there were no false positive 
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results. In the false negative group four were male and one was female. Of the 5 false 
negative results four were recorded in 2015, and one in 2014 (the only case in 2014 that met 
the inclusion criteria), and none were recorded in 2016. 
 
Table 3.8: Cross-tabulation of the Tri-line RT and ELISA results 
RT 
ELISA 
POSITIVE NEGATIVE Total 
POSITIVE 20 0 20 
NEGATIVE 5 20 25 
Total 25 20 45 
 
 
Given the low sample size the estimates of sensitivity and specificity were subject to wide 
confidence intervals as depicted in Table 3.9. To determine the validity and reliability of the 
Tri-line RT against the gold standard ELISA the rate of sensitivity, specificity, PPV, NPV, 
positive and negative likelihood ratios were determined. The sensitivity of Tri-line was 80% 
(CI: 59-93%) which indicates that 80% of patients were identified as HIV positive, and 
specificity was 100% (CI: 83-100%) indicating that all patients who were negative were 
identified as such. This is shown in Table 3.4. The PPV was 100% (CI: 83-100%) and NPV 
was 80% (CI: 65-90%). Specificity and PPV are high (albeit with wide confidence intervals), 
but sensitivity and NPV are lower than anticipated (Table 3.9).  
 
The positive likelihood ratio is the ratio between the probability of a positive test result given 
the presence of the disease and the probability of a positive test result given the absence of 
the disease, i.e. Sensitivity / (1-Specificity).  This was calculated as infinity since Specificity 
is 100%.  The negative likelihood ratio is the ratio between the probability of a negative test 
result given the presence of the disease and the probability of a negative test result given the 
absence of the disease, i.e. (1-Sensitivity) / Specificity (Table 3.9). 
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Table 3.9 Diagnostic indicators  
Indicator Estimate 95% CI  
Sensitivity 80% 59-93% 
Specificity 100% 83-100% 
PPV 100% 83-100% 
NPV 80% 65-90% 
Positive Likelihood Ratio infinity - 
Negative Likelihood Ratio 0.20 0.09-0.44 
Sensitivity, specificity, PPV, NPV, positive and negative likelihood ratios of the Rapid Test 
compared to the gold standard ELISA test. 
3.3 Discriminatory power of the Tri-line rapid test with reference to ELISA 
The results of the non-parametric ROC curve indicated the ROC area of 0.9 at 95% 
confidence interval (Figure 3.1 and Table 3.10). Table 3.10 outlines the details of the values 
represented in the ROC curve in Figure 3.3. They are shown as the area under the curve 
specifying the discriminatory power of the diagnostic test (Tri-line RT). 
 
Table 3.10: Details of ROC Curve in Figure 3.3 
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Figure 3.3: Receiver Operating Characteristic (ROC) Curve for Rapid Test compared to 
ELISA (Gold Standard) 
 
Summary of results 
 
The sensitivity of Tri-line was 80% (95% CI: 59-93%), and specificity was 100% (95% CI: 
83-100%). The calculated PPV was 100% and the NPV was 80%.  The discordant results 
were false negative, and none were false positive. The results of the non-parametric ROC 
curve demonstrated an ROC area of 0.9 at 95% confidence interval.  
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CHAPTER 4: Discussion  
4.1 Discussion  
In this study, of the 45 records with valid ELISA results, none had HIV positive results with 
the Tri-line test that turned out negative with ELISA. Hence the specificity and PPV in this 
study were found to be high, whilst sensitivity and NPV were found to be lower than 
anticipated, and this finding is congruent to other studies (Wolpaw, 2010, Patel et al., 2012, 
Bock et al., 2017). The estimates of sensitivity and specificity for this study were subject to 
wide confidence intervals as a result of the low sample size, which is expected in a pilot 
study.  
Although in this study high specificity of 100 % (95%CI 83-100%) was observed, with no 
false positive results with the Tri-line test, was observed, false positive results have been 
reported in other studies (Gray et al., 2007, Shanks et al., 2013, Klarkowski et al., 2014). 
Consequently, the retesting of patients already on ART is advocated to ensure that all patients 
have been accurately diagnosed. The high specificity in the study rules in HIV infection with 
a high degree of confidence for those testing positive with the Tri-line.  
False positive results are common in infants born to HIV mothers. Although there were three 
medical records where age was not reported, these were included based on reports from the 
Maxillo-Facial and oral surgery ward, in that there were no patients seen and tested for HIV 
who were < 18 months old. If individuals under 18 months were present they would have 
been excluded on the basis that PCR instead of RT would have been conducted.  
In the current study, the sensitivity was lower than the WHO recommended sensitivity of 
≥99%. The Tri-line test did not meet the sensitivity reported by the manufacturer of 100% 
(95% CI 99.2 % - 100%). This result implies an increased probability of missing HIV 
positive patients. This raises serious concerns and further studies should be conducted to 
determine the possible reasons for the underperformance of the Tri-line test. These 
uncertainties may result in the validity of the tests being questioned by patients and thus 
compromise efforts made to reduce the spread of the virus. The sensitivity and NPV were 
found to be 80% (95% CI: 59-93% and 65-90% respectively), inferring that patients who 
tested negative may in fact be HIV infected. This poses a serious impediment on the impact 
of intervention programmes as patients who falsely test negative may subsequently and 
unknowingly transmit the infection to others.   
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False negative results translate to missed opportunities to implement appropriate management 
with subsequent delays in the initiation of ART and continued spread of HIV. RTs that test 
for antibodies only can give false negative results when patients have not seroconverted, have 
agamaglobulinaemia, severe immunosuppression or are on HAART. This leaves health care 
workers in the frontline with an immense challenge of having to explain to individuals being 
tested that a negative result may not necessarily exclude the possibility of positive result at a 
later stage.  
The exact cause for the five false negative results in this study could not be determined. In 
other studies, the main contributing factor attributed to discordant false negative results was 
acute HIV infection (Adetunji et al., 2018). It is possible, based on the data collected, that the 
five false negative results could be linked to acute HIV infection, improper administration of 
Tri-line RT or severe immunosuppression in the patients tested. The latter is believed to be 
the most probable contributing factor in a patient who tested negative with the Tri-line test 
and positive with ELISA despite a CD4-T cell count of 36 cells/µL. Tests conducted during 
the early stages as opposed to later stages of HIV infection, have been shown to have lower 
sensitivity and may therefore produce false negative results. The aforementioned factors are 
feasible particularly because most patients were specifically referred for an HIV test by 
health care workers when HIV infection was suspected. Furthermore, the use of different 
testing algorithms in one setting as is the case at WOHC may be confusing and result in the 
manufacturer’s guidelines not being followed as prescribed. The recommended WHO testing 
algorithm that was also employed has its flaws. The algorithm can lead to misdiagnosis of 
HIV infection when the screening RT and the confirmatory RT gives a false positive or 
negative result. 
Therefore individuals presenting with group 1 lesions as described in the EC Clearing House 
classification, should as a standard protocol have testing inclusive of both the RT and ELISA 
test where RT is the first line test. This can be life-saving as was the case in the current study 
for two patients diagnosed with oral malignancies (plasmablastic lymphoma and Kaposi’s 
Sarcoma) strongly associated with HIV whose results were negative with the Tri-line test but 
positive with ELISA.  The wide spread use of RTs in high-risk, high-incidence populations is 
reported to be of limited benefit considering the possibility of missed infections (Wawer et 
al., 2005, Patel et al., 2012). The value of RTs should be continuously challenged so that 
better RTs with increased sensitivity and specificity are developed. Although the value of 
RTs may be questionable as stated above, the tests provide immediate results and optimize 
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intervention programmes. The challenge is with patients who test negative and opt not to 
subject themselves to additional tests even when they are at risk of being infected. As this 
current study demonstrated, the patients did not subject themselves to the ELISA test for 
various reasons and were accordingly excluded. 
This challenges the widespread use of RT in patients where there is a high index of suspicion 
for HIV infection given its failure to detect HIV infection in the early stages with resultant 
missed opportunities to interrupt onward HIV transmission and timeous management (Patel 
et al., 2012). The use of RTs in high risk populations should therefore be re-considered or 
other more sensitive tests explored for early identification of HIV infection, since individuals 
with early HIV infection are more likely to transmit HIV given the higher viraemia early in 
the disease process (Wawer et al., 2005).  
Similar to findings in the literature, the majority of HIV positive participants in this study 
were female (UNAIDS, 2009, Mbachu et al., 2015). The highest rates of HIV infection were 
between the ages of 20 and 41. This finding, having accounted for all other factors, aids in the 
profiling of patients most likely to be infected with HIV in our setting. Patients in this age 
group presenting with lesions associated with HIV, should have both the RT and ELISA test 
conducted as a precautionary measure.   
In most cases, it is not always possible to determine when an individual got exposed, so 
choosing the most appropriate test may be a challenge. Therefore considering that a negative 
RT result does not preclude the possibility of infection with HIV; tests with a high sensitivity 
and specificity, independent of serostatus or viral titre, would be ideal diagnostic tools to 
eliminate inaccurate HIV diagnoses which could have dire consequences for the patient and 
society (Granade et al., 2004). This is important as the achievement of prevention and 
treatment goals of HIV infection relies on individuals knowing their status, making HTS the 
gateway to a continuum of care (National HIV Testing Policy and Guidelines, 2015). Given 
the limitations of standard widely used RTs one is of the view that if the status quo remains, 
eradication of HIV infection will not be realized any time soon, one false negative result is 
one too many, given the prevalent high risk lifestyles.    
In a setting where laboratories are out of range, patients can be enrolled on HAART 
unnecessarily. At WOHC, patients testing HIV positive with RT are sent for ELISA to 
confirm the RT results; and in the Oral Medicine clinic given the high rate of negative results 
(anecdotal), patients presenting with lesions associated with HIV are also sent for ELISA 
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despite the RT results. There were some instances where patients were sent for CD4-T cell 
count only, which is of no use in the diagnosing HIV as a low CD4-T cell count can be seen 
in other conditions other than HIV. Requesting CD4-T cell count only or even viral load does 
not help exclude HIV infection. In this study one of the cases was that of a patient who 
presented with severe oral mucosal erosive lesions with a CD4-T cell count of 264 cells/µL 
and tested HIV negative with both the Tri-line and ELISA. It is thus important for clinicians 
to know what test to request for purposes of either diagnosing or excluding HIV infection.  
An understanding of factors contributing to HIV misdiagnosis in specific contexts is critical 
as it can aid health care providers and policy makers to come up with approaches that will 
address and prevent HIV misdiagnosis allowing the scale-up of HIV RT programmes 
(Johnson et al., 2017a). It is important that in the absence of newer advanced HIV testing 
algorithms, the current recommended testing algorithm is followed and that the appropriate 
WHO prequalified RTs are employed in HIV diagnostics.   
In view of the WHO recommendations that ART should be administered immediately after a 
positive HIV diagnosis regardless of the CD4-T cell count; preventing and addressing 
misdiagnosis is of paramount importance (Johnson et al., 2017a, Shanks et al., 2013). The 
“test and treat” approach is like a double edged sword on the one hand it can be life-saving 
when patients are truly positive and on the other,  it increases the risk of unwanted effects by 
initiating ART in patients who do not have HIV infection (Shanks et al., 2013). 
The oral health team can contribute towards addressing issues of misdiagnosis and reaching 
the goal of diagnosing 90% of people with HIV, by identifying those patients presenting with 
lesions strongly associated with HIV. The efforts to accelerate HIV diagnosis and linking 
individuals to treatment should be complemented by efforts to improve the quality of HTS, 
strengthening the use of validated testing algorithms and strategies (Johnson et al., 2017b). 
The HTS at the WOHC does not use one testing algorithm and the parallel testing algorithm 
is not followed as prescribed, mainly due to unavailability of the third RT recommended as a 
tiebreaker. Whilst repeating the tests two or three times using the same method each time 
may be redundant; Mbachu and colleagues in 2015, found in their study that the serial testing 
algorithm had a higher sensitivity. Their study showed that using an established algorithm in 
HIV screening and diagnosis improves the accuracy of the RT with regards to sensitivity, 
specificity, positive predictive value and negative predictive value (Mbachu et al., 2015). 
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There is no doubt that in a country like South Africa, plagued with multiple new infections 
daily, the 4th generation RT should be standard at all testing sites. Such RTs when compared 
to the use of separate tests for HIV antibody or p24 antigen alone would be an important tool 
for the diagnosis of HIV (Beelaert and Fransen, 2010). Hence given the expanded use of RTs 
in health facilities and at community level, one is of the view that the widespread use of the 
4
th
 generation RTs should be promoted. Although the 4
th
 generation RTs has distinct 
challenges, they address major deficiencies with an antibody only RT such as the Tri-line 
test. Their widespread use will stimulate further research into more advanced assays with 
high sensitivity and specificity that would be of great benefit in the fight against HIV 
infection.   
Studies on HIV RTs can help improve HIV testing and advance the development of 
algorithms for specific settings such as in oral health care. The HTS at the WOHC was found 
to be mainly via PICT with no CICT recorded cases. This is significant when one considers 
that 65534 patients were seen at the WOHC from 2014-2016 and only 111 were tested for 
HIV.  
This study has shown that although much improvement is deemed necessary with regards to 
use of RT, the results in this study indicating a ROC area under the curve of 0.9 at 95% CI, 
makes the Tri-line RT a clinically useful test. 
In a country with a high mortality rate of HIV infected individuals with associated diseases, 
access to HIV testing and diagnosis is life-saving and essential in combating the HIV 
pandemic. Rapid HIV testing increases the effectiveness of testing and prevention 
programmes. The introduction of RTs in resource-limited areas has resolved many logistical 
issues including limited access to laboratories, delayed results turnaround time, the 
complexity and costs of ELISA technology (Moodley et al., 2008). Increased access to rapid 
HIV tests however is of limited value if internal and external quality control measures are not 
monitored regularly. False results and incorrect diagnoses could undermine the public 
confidence in HIV testing with a subsequent negative impact on all HIV prevention, 
treatment and support programmes (Moodley et al., 2008). 
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Study limitations 
This was a retrospective review study which lends itself to all the limitations of these types of 
studies including a small sample size. The lack of complete data in the hospital records meant 
that a large number of medical records were excluded from the study. Of the 65534 patients 
seen at the WOHC from 2014 to 2016 only 111 according to obtained records were sent for 
HTS. The study focused on patients who had the HIV tests done at the WOHC, therefore 
patients who had the tests conducted elsewhere were excluded from the study. The primary 
research could not verify whether the manufacturer’s guidelines were adhered to, by the 
healthcare workers who conducted the RTs or if the RT kits used were defective or not. 
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Chapter 5. Conclusion and recommendations 
 
The sample size for this study was not enough to reach a concrete conclusion. However, on 
the basis of the results obtained within the limitations of the study, the Tri-line test showed 
lower sensitivity when compared to ELISA. The sensitivity observed was also lower than that 
recommended by WHO. The Tri-line test was however shown to be a useful clinical test as 
depicted on the ROC curve. The results of this study however should be interpreted in the 
context of its limitations which amongst others include a rather small sample size. The 
authors recommend that Tri-line RT is not used as the sole diagnostic test for HIV, especially 
where a negative result is registered with the RT.  
Studies on HIV RTs can help improve HIV testing and advance the development of 
algorithms for specific settings such as in oral health care. In order to reach targeted 
population presenting at the WOHC a variety of HTS modalities should be encouraged so 
that HTS is not only through PICT but CICT as well. In this way the WOHC being a tertiary 
clinic can play a significant role in up-scaling HTS, which can translate to HIV prevention 
and timeous management.  
The 4th generation RT can reliably detect HIV antibodies and antigens; therefore, it can be 
used for targeted HIV testing, enhance existing HIV testing programmes and provide timeous 
identification of HIV infection. The antibody RT can be used for screening and the 4th 
generation RT as a confirmatory test. The combo RT would be of great benefit in oral health 
centres where lesions strongly associated with HIV are seen, especially considering that this 
can present in the early stages of HIV infection prior seroconversion or during the late stages 
when antibodies titres are low, when antibody only RTs are most likely to give false negative 
results.  
For high risk individuals presenting with lesions strongly associated with HIV, and 
questionable lifestyle risks, ELISA should be standard especially at health facilities where the 
services are available. The dental staff working in clinics should thus be trained in HTS so as 
to facilitate diagnosis of HIV infection for timeous intervention. Patients seen in various 
departments at the WOHC should be encouraged to have HIV tests done and those 
considered to be at high risk or with lesions strongly associated with HIV should have blood 
drawn for ELISA even when results are negative. When false negative results are suspected 
patients should be encouraged to have the RT test repeated to avoid missed HIV diagnoses, 
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which can compromise the patient’s health and result in ongoing transmission of the virus 
(Bock et al., 2017).  
A standard protocol for patients presenting with oral lesions associated with HIV that 
involves the use of RT and ELISA in all circumstances, regardless of the RT result should be 
developed and instituted at the WOHC.  The protocol may be expanded and adopted as the 
standard protocol across oral health care centres. This will help ensure uniformity amongst 
clinicians and the HTS nurses; and compliance with acceptable protocols as advocated by the 
national department of health; which include standardization of the algorithm in order to 
avoid the tragic and harmful implications of unreliable testing strategies.  
The current study highlighted the important role that the oral health care team can play in 
HIV diagnosis, prevention and management through identification of those who are infected 
and present with oral lesions associated with HIV. To help with development and 
implementation of proposed strategies more studies are needed, that specifically look at RT 
used in the WOHC and/ or nationally, and oral manifestations of HIV. 
Good record keeping should be encouraged as it will aid future research in this area. Patients 
who refuse to be tested should be recorded and requested to sign a refusal of treatment form 
especially where it has an impact on their management going forward. The HTS nurses 
should be provided with lesions most commonly associated with HIV. The clinician referring 
patients for HTS should stipulate reasons for requesting HIV testing on the laboratory request 
form so that clarity may be sought from the referring clinician if a request for ELISA has not 
been specified. 
Other health personnel outside oral health should be familiarized with the EC Clearing House 
lesions to facilitate adequate intervention strategies. There is a need for personnel trained on 
HTS to be stationed at the WOHC where the general patients present to cater for all patients 
coming to the clinic who may want to make use of CITC and for those requiring PICT. For 
relative ease of access there may be a need for government to establish laboratory services at 
major testing centres. 
The challenges faced with RTs and difficulties with QA can be minimized by increasing 
training and oversight. It should be borne in mind that even with optimal QA measures the 
accuracy of on-site RT can never be perfect (Pilcher et al., 2010). To ensure the efficiency of 
RTs there should be an improvement in the reporting of misdiagnoses, so that efforts can be 
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made to prevent and address them. Regular quality control of RTs is also crucial and studies 
reflecting their accuracy may validate or invalidate the use of RTs. Public confidence may be 
enhanced by studies evaluating the accuracy of RTs used in their setting to address issues 
relating to the distrust of testing programmes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
6. References 
Agbelusi, G.A., Eweka, O.M., Umeizudike, K.A., et al. (2013). Oral Manifestations of 
HIV, Current Perspectives in HIV Infection, Dr. Shailendra K.  Saxena (Ed.), InTech, 
DOI: 10.5772/52941. Available from: https://www.intechopen.com/books/current-
perspectives-in-hiv-infection/oral-manifestations-of-hiv 
Adetunji, A.A, Kuti, M.A, Audu, R.A. (2018). Discordant rapid HIV tests: lessons from a 
low-resource community. HIV Medicine, 19, 72-76. 
Beelaert, C., Fransen, K. (2010). Evaluation of a rapid and simple fourth-generation HIV 
screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 
and HIV-2. Journal of Virological Methods, 168, 218–222. 
Bock, P., Phiri, C., Piwowar-Manning, E., et al. (2017). Understanding low sensitivity of 
community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in 
Zambia and South Africa. Journal of the International AIDS Society, 20(Suppl 6), 21780.  
Bor, J., Herbst, A. J., Newel, M.L., et al. (2013). Increases in adult life expectancy in 
rural South Africa: valuing the scale-up of treatment. Science 339 (6122): 961-965. 
Branson, B. (2000). Rapid tests for HIV antibody. AIDS Rev, 2, 76–83. 
Branson, B.M., Owen, S.M., Wesolowski, L.G., et al. (2014). Centers for Disease Control 
and Prevention and Association of Public Health Laboratories. Laboratory Testing for the 
Diagnosis of HIV Infection: Updated Recommendations. Available at 
http://stacks.cdc.gov/view/cdc/23447.  
Chetty, V., Moodley, D., Chuturgoon, A.(2012). Evaluation of a 4th generation rapid HIV 
test for earlier and reliable detection of HIV infection in pregnancy. Journal of Clinical 
Virology,54, 180– 184. 
EC-Clearinghouse on oral Problems Related to HIV Infection and WHO Collaboration 
center on oral manifestations of the immunodeficiency Virus (ECC/WHO) (1993): 
Classification and diagnostic criteria for oral lesions in HIV infection. Journal of Oral 
Patholology and Medicine, 22(7), 289-91. 
38 
 
Eshleman, S.H., Piwowar-Manning, E., Sivay, M.V., et al. (2018). Performance of the 
BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. Journal of Clinical 
Virology, 99-100, 67-70. 
Fan, J., Upadhye, S., Worster, A. (2006). Understanding receiver operating characteristic 
(ROC) curves. Canadian Journal of Emergency Medicine, 8(1), 19–20. 
Faul, F., Erdfelder, E., Lang, A.G., et al. (2007) G*Power 3: A flexible statistical power 
analysis program for the social, behavioral, and biomedical sciences. Behavior Research 
Methods, 39, 175-191. 
Ferrando, P. J. (2012) ‘Assessing the discriminating power of item and test scores in the 
linear factor-analysis model’, Psicológica, 33, pp. 111–134. 
Granade, T.C., Parekh, B.S., Phillips, S.K., et al. (2004). Performance of the OraQuick® 
and Hema-Strip® rapid HIV antibody detection assays by non-laboratorians. Journal of 
Clinical Virology, 30, 229–232. 
Gray, R.H., Makumbi, F., Serwadda, D., et al. (2007). Limitations of rapid HIV-1 tests 
during screening for trials in Uganda: diagnostic test accuracy study. British Medical 
Journal, 612(335). 
Greenspan, J.S., Barr, C.E., Sciubba, J.J., et al. (1992). Oral manifestations of HIV 
infection. Oral Surg Oral Med Oral Pathol, 73, 142-144. 
Hajian-Tilaki, K. (2013). Receiver operating characteristic (ROC) curve analysis for 
medical diagnostic test evaluation. Caspian Journal of Internal Medicine, 4(2), 627–635. 
https://doi.org/10.1017/CBO9781107415324.004 
Jackson, D., Naik, R., Tabana, H., et al. (2013).  Quality of home-based rapid HIV testing 
by community lay counsellors in a rural district of South Africa. Journal Int AIDS Soc, 
14(16).  
Johnson, C., Fonner, V., Sands, A., et al. (2015). ANNEX 14. A report on the 
misdiagnosis of HIV status. WHO/HIV/2015.33. World Health Organization 2015. 
39 
 
aJohnson, C.C., Dalal, S., Baggaley, R., et al. (2017). A public health approach to 
addressing and preventing misdiagnosis in the scale-up of HIV rapid testing programmes. 
Journal of the International AIDS Society, 20(Suppl 6),22190 
bJohnson, C.C, Fonner, V., Sands, A., et al. (2017). To err is human, to correct is public 
health: identifying poor quality testing and misdiagnosis of HIV status. Journal of the 
International AIDS Society, 20(Suppl 6),21755. 
Kassler, W.J., Alwano-Edyegu, M.G., Marum, E., et al. (1998). Rapid HIV testing with 
same-day results: a field trial in Uganda. Int J STD AIDS, 9,134–8.  
Kassler, W.J., Dillon, B.A., Haley, C., et al. (1997). On-site, rapid HIV testing with same-
day results and counselling. AIDS, 11, 1045–51.  
Klarkowski, D., O’Brien, D.P., Shanks, L., et al. (2014). Causes of false positive HIV 
rapid diagnostic test results. Expert Rev Anti Infect Ther, 12, 49–62. 
Lihana, R.W., Khamadi, S.A., Lwembe, R.M., et al. (2009): HIV-1 subtype and viral 
tropism determination for evaluating antiretroviral therapy options: an analysis of 
archived Kenyan blood samples. BMC Infec. Dis, 9,215-217. 
Louie, B., Wong, E., Klausner, J.D., et al. (2008). Assessment of Rapid Tests for 
Detection of Human Immunodeficiency Virus-Specific Antibodies in Recently Infected 
Individuals. Journal of clinical microbiology,1494–1497. 
 Maeve, M.C., Greenspan, J., Challacombe, S.J. (2005). Oral lesions in infection with 
HIV. Bulletin of the World Health Organisation, 83, 700-706. 
Mbachu, I.I., Udigwe, G., Joseph, I. (2015). The evaluation of accuracy of serial rapid 
HIV test algorithm in the diagnosis of HIV antibodies among pregnant women in South 
East Nigeria. BMC Res Notes, 8,557 
Mehra, B., Bhattar, S., Bhalla, P., et al. (2014). Rawat D. Rapid tests versus ELISA for 
screening of HIV infection: our experience from a voluntary counselling and testing 
facility of a tertiary care centre in North India. Hindawi ISRN AIDS 2014, 296840.  
40 
 
Miller, S. (2015). Laboratory diagnosis of HIV infection: immunoassays. Lancet 
Laboratories South Africa.  
Moodley, D., Moodley, P., Ndabandaba, T., et al. (2008). Reliability of HIV rapid tests is 
user dependent. SAMJ, 98(9),707-709.  
Molesworth, A.M., Ndhlovu, R., Banda, E., et al. (2010). High accuracy of home-based 
community rapid HIV testing in rural Malawi. J Acquir Immune Defic Syndr, 15, 55(5), 
625–30. 
Mwisongo, A., Peltzer, K., Mohlabane, N., et al. (2016). The quality of rapid HIV testing 
in South Africa: an assessment of testers' compliance. Afr Health Sci, 3, 646–654.  
National Department of Health. (2015). South African National HIV testing services 
(HTS): Policy and Guidelines.  
 
National Department of Health. (2016). HIV Testing Services Policy and Guidelines. 
 
New guide: HIV testing and sexual transmission. http://i-
base.info/guides/files/2011/12/Testing-Appendices-FINAL-Feb2012.pdf 
 
Patel, P., Bennett, B., Sullivanc, T., et al. (2012). For the CDC AHI Study Group. Rapid 
HIV screening: Missed opportunities for HIV diagnosis and prevention. Journal of 
Clinical Virology, 54, 42– 47. 
Pilcher, D., Christopoulos, K. A., Golden, M. (2010). Public health rationale for Rapid 
Nucleic Acid or p24 Antigen Tests for HIV. Journal of Infectious Diseases, 201(S1):S7–
S17. 
Piwowar-Manning, E.M., Tustin, N.B., Sikateyo, P., et al. (2010). Validation of Rapid 
HIV Antibody Tests in 5 African Countries. Journal of the International Association of 
Physicians in AIDS Care, 9(3), 170-172. 
 
Shangase, L., Feller, L., Blignaut, E. (2004). Necrotising ulcerative 
gingivitis/periodontitis as indicators of HIV-infection. SADJ, 59(3),105-8. 
 
41 
 
Shanks, L., Klarkowski, D., O’Brien, D.P. (2013). False positive HIV diagnoses in 
resource limited settings: operational lessons learned for HIV programmes. PLoS ONE 
2013; 8: e59906. 
 
Shisana, O., Rehle, T., Simbayi, L.C., et al. (2014). South African National HIV 
Prevalence, Incidence and Behaviour Survey, 2012. 
 
UNAIDS report. (2009). AIDS epidemic update. 
UNAIDS. Global AIDS update. Geneva: Joint United Nations Programme on HIV/AIDS. 
(2016). 
Wawer, M.J., Gray, R.H., Sewankambo, N.K., et al. (2005). Rates of HIV-1 transmission 
per coital act, by stage of HIV-1 infection, in Rakai, Uganda. Journal of Infectious 
Diseases, 191(9), 1403–1409. 
 
Wolpaw, B.J., Mathews, C., Chopra, M., et al. (2010). The failure of routine rapid HIV 
testing: a case study of improving low sensitivity in the field. BMC Health Services 
Research, 10(73). 
 
World Health Organisation. (2004). Rapid HIV tests: guidelines for use in HIV testing 
and counselling services in resource-constrained settings WHO Press, World Health 
Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. Geneva: WHO, 2004. 
 
World Health Organization. (2005). Guidelines for assuring the accuracy and reliability 
of HIV rapid testing. Geneva, Switzerland: World Health Organization, 2005. 
 
WHO Prequalification of Diagnostics Programme PUBLIC REPORT. (2017). Product: 
ABON™ HIV 1/2/O Tri-Line Human Immunodeficiency Virus Rapid Test Device 
Number: PQDx 0141-051-00. 
 
 
 
42 
 
APPENDIX A: 
Ethics Clearance Certificate 
  
 
 
43 
 
APPENDIX B 
 
Protocol Approval 
 
 
  
44 
 
APPENDIX C 
Approval from the School of Oral Health Science  
 
 
 
 
 
 
 
 
45 
 
APPENDIX D   
Data Collection Sheet 
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